Victoza vs. Byetta in type 2 diabetes

In LEAD-6 trial, about 500 patients with type 2 diabetes were followed for 26 weeks. Participants were randomized to receive either Victoza 1.8 mg once daily or Byetta 10 mcg twice daily. Results indicated relative superiority of Victoza over Byetta as shown by improved A1c (-Δ1.1% vs -Δ0.8%) and better convenience and tolerability.



slide 1.jpg

slide 2.jpeg

slide 3.jpeg

Slide 4.jpg

Slide 5.jpg

slide 7.jpg

Slide 8.png

slide 9.png

Slide 10.png

slide 11.png

Slide 12.png

Slide 13.png

Slide 14.png

Slide 15.png

Slide 16.png